22 May 2013
Keywords: Celgene, Pomalyst, Pomalidomide, Multiple myeloma, USA, FDA
Article | 11 February 2013
The US Food and Drug Administration on Friday approved biotech firm Celgene’s (Nasdaq: CELG) Pomalyst (pomalidomide) to treat ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
11 February 2013
21 May 2013
© 2013 thepharmaletter.com